Metastatic breast cancer (MBC) management remains a complex challenge for oncologists globally. While standard care involves waiting for 8 to 12 weeks to assess treatment efficacy via CT scans, the FDG-PET metastatic breast cancer study (IMPACT-MBC) suggests a faster alternative. Researchers recently evaluated whether early metabolic changes seen on FDG-PET at just two weeks could predict long-term clinical outcomes and survival rates more effectively than standard diagnostics.

The multicenter IMPACT-MBC trial involved 200 patients with newly diagnosed, non-rapidly progressive metastatic disease. Before starting first-line systemic therapy, every participant underwent baseline assessments including biopsy and PET/CT imaging. Importantly, clinicians performed an early FDG-PET scan only two weeks after treatment began. They subsequently followed this with a standard CT response evaluation at the eight-week mark to compare the results.

Results from the trial demonstrated exceptional predictive accuracy. A \"non-progressive disease\" status on the 2-week FDG-PET scan showed a negative predictive value (NPV) of 94.7% for the 8-week CT results. This high accuracy remained consistent across all MBC subtypes, including the notoriously difficult-to-evaluate bone-only disease. Furthermore, patients showing metabolic stability or response at two weeks enjoyed significantly longer survival. Specifically, these patients had a median progression-free survival (PFS) of 19.4 months compared to only 4.1 months for metabolic non-responders.

Clinical Utility of FDG-PET Metastatic Breast Cancer Scans

The ability to identify poor responders within 14 days of starting therapy could revolutionize clinical decision-making. Consequently, doctors might avoid several weeks of ineffective and potentially toxic treatment for patients who are not benefiting from their current regimen. The trial showed that patients who did not respond metabolically at two weeks had a median overall survival (OS) of just 18.5 months. In contrast, those with early metabolic response survived nearly 40 months. Therefore, incorporating early molecular imaging provides a much clearer prognostic picture than waiting for anatomic changes on CT.

Notably, the IMPACT-MBC trial highlights that early FDG-PET is not just a staging tool but a dynamic predictor of therapy success. While standard diagnostic evaluation remains the norm, these findings suggest that early metabolic monitoring should be considered to personalize patient care. Ultimately, this approach could improve quality of life by allowing for earlier pivots to second-line therapies when initial treatments fail.

Why is a 2-week FDG-PET scan better than an 8-week CT?

Metabolic changes in cancer cells usually occur much faster than physical tumor shrinkage. Therefore, FDG-PET can detect whether a drug is working at a cellular level just 14 days into treatment, whereas CT scans require months to confirm anatomical changes.

Does early PET response work for all breast cancer subtypes?

Yes, the IMPACT-MBC trial found that the high negative predictive value of early PET scans was consistent across all MBC subtypes, including hormone receptor-positive, HER2-positive, and triple-negative cases.

Can this approach help patients with bone-only metastases?

Bone metastases are often difficult to measure on standard CT because bone density changes slowly. However, FDG-PET measures metabolic activity directly, making it a highly effective tool for assessing treatment response in bone-dominant disease.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship between the reader and the publisher. Refer to the latest local and national guidelines for clinical practice.

References

van Geel JJL et al. 18F-Fluorodeoxyglucose Positron Emission Tomography for Estimating Outcomes After Initial Treatment for Metastatic Breast Cancer: A Nonrandomized Clinical Cohort Trial. JAMA Oncol. 2026 Apr 16. doi: 10.1001/jamaoncol.2026.0767. PMID: 41989806.

Vogsen M, Naghavi-Behzad M, Harbo FG, et al. 2-[18F]FDG-PET/CT is a better predictor of survival than conventional CT: a prospective study of response monitoring in metastatic breast cancer. Sci Rep. 2023;13(1):5552.

Specht JM, Jacene H, et al. Metabolic imaging enables early response prediction in bone-dominant metastatic breast cancer: Results of the FEATURE trial. Presented at San Antonio Breast Cancer Symposium 2025.